U.S. pharma large copyright scrapped two experimental weight loss drugs past calendar year—a when-daily capsule, lotiglipron, as a result of elevated liver enzymes plus a two times-every day tablet, danuglipron, due to potent Uncomfortable side effects—but CEO Albert Bourla has said the company is decided to “Perform and get” from the weigh